Passage Bio (NASDAQ:ZNTL) shares dropped 1.2% on Monday . The company traded as low as $47.83 and last traded at $47.29, approximately 4,037 shares traded hands during trading. A decline of 99% from the average daily volume of 328,337 shares. The stock had previously closed at $47.85.
ZNTL has been the topic of a number of recent analyst reports. Zacks Investment Research reissued a “hold” rating and set a $47.00 price target on shares of Passage Bio in a research report on Saturday, May 30th. Guggenheim began coverage on shares of Passage Bio in a research report on Tuesday, April 28th. They issued a “buy” rating and a $45.00 price objective on the stock. Jefferies Financial Group began coverage on shares of Passage Bio in a research report on Tuesday, April 28th. They issued a “buy” rating and a $41.00 price objective on the stock. SVB Leerink began coverage on shares of Passage Bio in a research report on Tuesday, April 28th. They issued an “outperform” rating and a $45.00 price objective on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Passage Bio in a research report on Tuesday, May 12th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $44.60.
The firm has a 50 day moving average price of $44.91.
In other Passage Bio news, major shareholder Global Investors Lp Viking bought 725,000 shares of Passage Bio stock in a transaction dated Tuesday, April 7th. The stock was purchased at an average price of $24.80 per share, for a total transaction of $17,980,000.00.
About Passage Bio (NASDAQ:ZNTL)
Zentalis Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of breast cancer.
See Also: What is the FTSE 100 index?
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.